Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

NCT02456701 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer

Interventions

BIOLOGICAL: KTN3379
DRUG: vemurafenib

Sponsor

Celldex Therapeutics

Collaborators

[object Object]